SCHEMBL3351112

SCHEMBL3351112

O=C(O)N(O)CCCNCc1ccc(C(F)(F)F)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM6B O15054 1/20 0.46
KDM4A O75164 1/20 0.46
KDM2A Q9Y2K7 1/20 0.46
SCN8A Q9UQD0 1/20 0.46
TMEM97 Q5BJF2 1/20 0.45
SIGMAR1 Q99720 1/20 0.45
LSS P48449 1/20 0.45
FFAR1 O14842 1/20 0.43
MTOR P42345 1/20 0.43
HDAC3 O15379 1/20 0.42
HDAC1 Q13547 1/20 0.42
HDAC2 Q92769 1/20 0.42
HDAC10 Q969S8 1/20 0.42
HDAC11 Q96DB2 1/20 0.42
HDAC8 Q9BY41 1/20 0.42
HDAC6 Q9UBN7 1/20 0.42
S1PR1 P21453 1/20 0.42
ASPH Q12797 1/20 0.41
KDM8 Q8N371 1/20 0.41
SLC6A5 Q9Y345 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3355237 0.84 MEN1 (0.53) SCN8AFFAR1MEN1KMT2AMAPK14
SCHEMBL3350267 0.83 SCN8A (0.50) KDM6BKDM4AKDM2ASCN8ASLC6A5
SCHEMBL3356470 0.81 CHRM2 (0.56) KDM6BKDM4AKDM2ATMEM97SIGMAR1
Toluene SCHEMBL3916489 0.78 CHRM2 (0.51) KDM6BKDM4AKDM2ATMEM97SIGMAR1
SCHEMBL3357890 0.78 CHRM2 (0.59) KDM6BKDM4AKDM2ASCN8ASIGMAR1
SCHEMBL3353121 0.77 CHRM2 (0.62) KDM6BKDM4AKDM2ATMEM97SIGMAR1
SCHEMBL5939610 0.76 S1PR1 (0.61) SCN8AFFAR1MTORHDAC3HDAC1
SCHEMBL1846372 0.75 SMN1; SMN2 (0.50) SCN8AFFAR1MTORNAMPT
SCHEMBL16269079 0.75 MTOR (0.51) SCN8ALSSFFAR1MTORHDAC3
SCHEMBL4423057 0.74 SCN8A (0.51) SCN8ATMEM97SIGMAR1LSSS1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7727997-B2 N,N′-substituted-1,3-diamino-2-hydroxypropane derivatives ELAN PHARMACEUTICALS, INC. (US) 2010-06-01 US disclosed
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease ELAN PHARMACEUTICALS, INC. 2007-09-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213316-A1 Compounds that are effective inhibitors of beta-secretase; inhibitors of beta-secretase-mediated cleavage of amyloid precursor proteins; effective inhibitors of A beta production, and/or are effective to reduce amyloid beta deposits or plaques; treatment of disorders such as Alzheimer's Disease BACE1, BACE2, APP KDM6B 4499/4885KDM4A 4325/4885KDM2A 4390/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.